252263-98-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(Boc-aMinoethyloxy)benzonitrile is used as a protecting group in peptide synthesis for the amine group in amino acids. It is crucial in the preparation of various pharmaceuticals, ensuring the selective protection and modification of specific functional groups within complex molecular structures.
Used in Organic Chemistry:
3-(Boc-aMinoethyloxy)benzonitrile is used as a key building block in the synthesis of complex organic compounds. Its ability to selectively protect and modify specific functional groups allows for the creation of intricate molecular structures, contributing to advancements in organic chemistry research and development.

Upstream product

• 873-62-1 m-cyanophenol 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 71999-74-1 tert-butyl N-(2-chloroethyl)carbamate 
• 39684-80-5 2-(tert-butoxycarbonylamino)ethyl bromide 
• 158690-56-3 2-(tert-butoxycarbonylamino)ethyl-4-methylbenzenesulfonate 
• 6952-59-6 3-cyanobromobenzene 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 120351-94-2 2-(3-cyanophenoxy)ethanamine 
• 538335-82-9 N-[2-(3-cyanophenoxy)ethyl]benzamide 
• 210961-79-8 N-[2-(3-cyanophenoxy)ethyl]-4-cyanobenzamide 
• 210962-10-0 N-[2-(3-cyanophenoxy)ethyl]-1-(4-pyridyl)piperidine-4-carboxamide 
• 210962-01-9 N-[2-(3-cyanophenoxy)ethyl]-4-(1-pyrrolidinecarbonyl)benzamide 
• 210958-96-6 N-[2-(3-amidinophenoxy)ethyl]-4-(4-piperidyloxy)benzamide 
• 210962-73-5 N-[2-(3-cyanophenoxy)ethyl]-4-(1-tert-butoxycarbonyl-4-piperidyloxy)benzamide 
• 476352-36-0 2'-sulfamoyl-biphenyl-4-carboxylic acid [2-(3-cyano-phenoxy)-ethyl]-methyl-amide 
• 476352-32-6 2'-sulfamoyl-biphenyl-4-carboxylic acid [2-(3-cyano-phenoxy)-ethyl]-amide 
• 309930-31-2 2'-tert-butylsulfamoyl-biphenyl-4-carboxylic acid [2-(3-cyano-phenoxy)-ethyl]-amide 
• 476352-40-6 [[2-(3-cyano-phenoxy)-ethyl]-(2'-sulfamoyl-biphenyl-4-carbonyl)-amino]-acetic acid methyl ester 

Relevant academic research and scientific papers

Palladium Catalyzed C?O Coupling of Amino Alcohols for the Synthesis of Aryl Ethers

Amine containing aryl ethers are common pharmacophore motifs that continue to emerge from drug discovery efforts. As amino alcohols are readily available building blocks, practical methodologies for incorporating them into more complex structures are highly desirable. We report our efforts to explore the application of Pd-catalyzed C?O coupling methods to the arylation of 1,2- and 1,3-amino alcohols. We established general and reliable conditions, under which we explored the scope and limitations of the transformation. The insights gained have been valuable in employing this methodology within a fast-moving drug discovery environment, which we anticipate will be of general interest to the synthesis and catalysis communities.

Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach

A virtual screening conducted with nearly 4?000?000 compounds from lead-like and fragment-like subsets enabled the identification of a small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas disease. Subsequent comprehensive structure-based drug design and structure-activity relationship studies led to the discovery of carbamoyl imidazoles as potent, reversible, and competitive cruzain inhibitors. The most potent carbamoyl imidazole inhibitor (45) exhibited high affinity with a Ki value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, the most promising compounds reduced parasite burden in vivo and showed no toxicity at a dose of 100 mg/kg. These carbamoyl imidazoles are structurally attractive, nonpeptidic, and easy to prepare and synthetically modify. Finally, these results further advance our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.

Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids

An inhibitor of factor Xa (fXa), the m-substituted benzamidine AXC1578 (1a), was structurally modified with the aim of increasing its potency. In particular, pyruvic acid and propionic acid substituents were incorporated into the P1 benzamidine moiety to

Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors

Monoamidine FXa inhibitors 3 were designed and synthesized. SAR studies and molecular modeling led to the design of conformationally constrained diaryl ethers 4 and 5, as well as benzopyrrolidinone 7 as potent FXa inhibitors. The monoamidines show high efficacy in a DVT model, but lack desirable oral bioavailability. The benzopyrrolidinone-based aminoisoquinolines 8 do not show significant improvement in oral bioavailability.

Benzamidine derivatives

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of the following formulae or analogs thereof, i. e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants.